Understanding how Listeria seeligeri uses CRISPR-Cas13 to fight off viruses
CRISPR-Cas13 immunity in Listeria seeligeri
This study looks at how a special system in bacteria helps them fight off viruses, which could lead to new ways to treat bacterial infections and boost our immune responses against viruses.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11086000 on NIH RePORTER |
What this research studies
This research investigates the CRISPR-Cas13 immune system in the bacterium Listeria seeligeri, focusing on how it recognizes and destroys viral RNA. By studying this natural bacterial model, researchers aim to uncover the complex interactions between bacterial immunity and viral infections. The approach involves examining how the Cas13 enzyme activates to cleave viral RNA, preventing the virus from replicating and harming the bacterial host. This could provide insights into new strategies for combating bacterial infections and enhancing antiviral immunity.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research would include individuals with infections caused by antibiotic-resistant bacteria or those interested in advanced therapeutic strategies.
Not a fit: Patients with viral infections that do not involve bacterial co-infections may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that enhance bacterial resistance to viral infections, potentially improving patient outcomes in related conditions.
How similar studies have performed: Other research has shown promise in using CRISPR systems for bacterial immunity, indicating that this approach could yield significant insights and advancements.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Meeske, Alexander Jacob — University of Washington
- Study coordinator: Meeske, Alexander Jacob
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.